Treatment of pulmonary arterial hypertension with circulating angiogenic cells
In conclusion, CAC therapy was not associated with increased survival and did not result in either clinical or histological benefits. Future studies should be geared toward either earlier therapeutic time points with varying doses of unmodified CACs or genetically modified cells as a means of delivery of factors to the pulmonary arterial circulation. (Source: AJP: Lung Cellular and Molecular Physiology)